{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:15:54Z","timestamp":1772165754446,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The present study compared the effectiveness and toxicity of two treatment modalities, namely radiotherapy combined with nimotuzumab (N) and chemoradiotherapy (CRT) in patients with locally recurrent nasopharyngeal carcinoma (LR-NPC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with LR-NPC who were treated with radiotherapy were retrospectively enrolled from January 2015 to December 2018. The treatment included radiotherapy combined with N or platinum-based induction chemotherapy and\/or concurrent chemotherapy. The comparison of survival and toxicity between the two treatment modalities was evaluated using the log-rank and chi-squared tests. Overall survival (OS) was the primary endpoint.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 87 patients were included, of whom 32 and 55 were divided into the N group and the CRT group, respectively. No significant differences were noted in the survival rate between the N and the CRT groups (4-year OS rates, 37.1% vs. 40.7%, respectively;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.735). Mild to moderate acute complications were common during the radiation period and mainly included mucositis and xerostomia. The majority of the acute toxic reactions were tolerated well. A total of 48 patients (55.2%) demonstrated late radiation injuries of grade\u2009\u2265\u20093, including 12 patients (37.5%) in the N group and 36 patients (66.5%) in the CRT group. The CRT group exhibited significantly higher incidence of severe late radiation injuries compared with that of the N group (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.011).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Radiotherapy combined with N did not appear to enhance treatment efficacy compared with CRT in patients with LR-NPC. However, radiotherapy combined with N may be superior to CRT due to its lower incidence of acute and late toxicities. Further studies are required to confirm the current findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-021-08995-y","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T13:32:03Z","timestamp":1638279123000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparison of radiotherapy combined with nimotuzumab vs. chemoradiotherapy for locally recurrent nasopharyngeal carcinoma"],"prefix":"10.1186","volume":"21","author":[{"given":"Jing-Feng","family":"Zong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian-Dong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiong-Jiao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han-Chuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bi-Juan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiao-Juan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cai-Rong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Ji","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shao-Jun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,25]]},"reference":[{"issue":"10192","key":"8995_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"Y-P Chen","year":"2019","unstructured":"Chen Y-P, Chan ATC, Le Q-T, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64\u201380.","journal-title":"Lancet"},{"key":"8995_CR2","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.2147\/OTT.S188148","volume":"12","author":"F Perri","year":"2019","unstructured":"Perri F. Della Vittoria Scarpati G, Caponigro F, Ionna F, Longo F, Buonopane S, Muto P, Di Marzo M, Pisconti S, Solla R: management of recurrent nasopharyngeal carcinoma: current perspectives. OncoTargets and therapy. 2019;12:1583\u201391.","journal-title":"OncoTargets and therapy"},{"issue":"9","key":"8995_CR3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11912-020-00949-0","volume":"22","author":"CY Hao","year":"2020","unstructured":"Hao CY, Hao SP. The management of rNPC: salvage surgery vs. Re-irradiation Curr Oncol Rep. 2020;22(9):86.","journal-title":"Re-irradiation Curr Oncol Rep"},{"issue":"3","key":"8995_CR4","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S1470-2045(20)30673-2","volume":"22","author":"Y-P Liu","year":"2021","unstructured":"Liu Y-P, Wen Y-H, Tang J, Wei Y, You R, Zhu X-L, et al. Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet Oncology. 2021;22(3):381\u201390.","journal-title":"The Lancet Oncology"},{"issue":"11","key":"8995_CR5","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1002\/hed.26397","volume":"42","author":"G Li","year":"2020","unstructured":"Li G, Wang J, Tang H, Han R, Zhao Y, Wang X, et al. Comparing endoscopic surgeries with open surgeries in terms of effectiveness and safety in salvaging residual or recurrent nasopharyngeal cancer: systematic review and meta-analysis. Head & neck. 2020;42(11):3415\u201326.","journal-title":"Head & neck"},{"issue":"3","key":"8995_CR6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.radonc.2015.04.024","volume":"115","author":"R You","year":"2015","unstructured":"You R, Zou X, Hua YJ, Han F, Li L, Zhao C, et al. Salvage endoscopic nasopharyngectomy is superior to intensity-modulated radiation therapy for local recurrence of selected T1-T3 nasopharyngeal carcinoma - a case-matched comparison. Radiother Oncol. 2015;115(3):399\u2013406.","journal-title":"Radiother Oncol"},{"issue":"10","key":"8995_CR7","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/hed.25892","volume":"41","author":"WT Ng","year":"2019","unstructured":"Ng WT, Wong ECY, Cheung AKW, Chow JCH, Poon DMC, Lai JWY, et al. Patterns of care and treatment outcomes for local recurrence of NPC after definite IMRT-A study by the HKNPCSG. Head & neck. 2019;41(10):3661\u20139.","journal-title":"Head & neck"},{"issue":"3","key":"8995_CR8","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/hed.24993","volume":"40","author":"YH Leong","year":"2018","unstructured":"Leong YH, Soon YY, Lee KM, Wong LC, Tham IWK, Ho FCH. Long-term outcomes after reirradiation in nasopharyngeal carcinoma with intensity-modulated radiotherapy: a meta-analysis. Head & neck. 2018;40(3):622\u201331.","journal-title":"Head & neck"},{"issue":"3","key":"8995_CR9","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s10555-017-9687-8","volume":"36","author":"MJ Xu","year":"2017","unstructured":"Xu MJ, Johnson DE, Grandis JR. EGFR-targeted therapies in the post-genomic era. Cancer Metastasis Rev. 2017;36(3):463\u201373.","journal-title":"Cancer Metastasis Rev"},{"key":"8995_CR10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13046-015-0251-5","volume":"34","author":"F Sevelda","year":"2015","unstructured":"Sevelda F, Mayr L, Kubista B, Lotsch D, van Schoonhoven S, Windhager R, et al. EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance. J Exp Clin Cancer Res. 2015;34:134.","journal-title":"J Exp Clin Cancer Res"},{"key":"8995_CR11","doi-asserted-by":"crossref","unstructured":"Aichler M, Motschmann M, J\u00fctting U, Luber B, Becker K, Ott K, Lordick F, Langer R, Feith M, Siewert J et al: Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy 2014, 5(16):6620\u20136632.","DOI":"10.18632\/oncotarget.2268"},{"key":"8995_CR12","doi-asserted-by":"crossref","first-page":"107327482198930","DOI":"10.1177\/1073274821989301","volume":"28","author":"R Liang","year":"2021","unstructured":"Liang R, Yang L, Zhu X. Nimotuzumab, an anti-EGFR monoclonal antibody, in the treatment of nasopharyngeal carcinoma. Cancer Control. 2021;28:1073274821989301.","journal-title":"Cancer Control"},{"issue":"8","key":"8995_CR13","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/1759-7714.12789","volume":"9","author":"X Si","year":"2018","unstructured":"Si X, Wu S, Wang H, Zhang X, Wang M, Zeng X, et al. Nimotuzumab combined with chemotherapy as first-line treatment for advanced lung squamous cell carcinoma. Thorac Cancer. 2018;9(8):1056\u201361.","journal-title":"Thorac Cancer"},{"key":"8995_CR14","doi-asserted-by":"crossref","unstructured":"Zhi-Qiang W, Qi M, Ji-Bin L, Rui Y, You-Ping L, Rui S, Guang-Yuan H, Ming-Yuan C, Yi-Jun H: The long-term survival of patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT with or without Nimotuzumab: a propensity score-matched analysis. BMC Cancer 2019, 19(1).","DOI":"10.1186\/s12885-019-6156-5"},{"key":"8995_CR15","doi-asserted-by":"publisher","first-page":"110649","DOI":"10.1016\/j.biopha.2020.110649","volume":"131","author":"X Chen","year":"2020","unstructured":"Chen X, Liang R, Zhu X. Anti-EGFR therapies in nasopharyngeal carcinoma. Biomed Pharmacother. 2020;131:110649.","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"8995_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070727","volume":"8","author":"YY Qu","year":"2013","unstructured":"Qu YY, Hu SL, Xu XY, Wang RZ, Yu HY, Xu JY, et al. Nimotuzumab enhances the radiosensitivity of cancer cells in vitro by inhibiting radiation-induced DNA damage repair. PLoS One. 2013;8(8):e70727.","journal-title":"PLoS One"},{"issue":"4","key":"8995_CR17","doi-asserted-by":"publisher","first-page":"373","DOI":"10.4161\/cbt.11.4.14097","volume":"11","author":"G Garrido","year":"2011","unstructured":"Garrido G, Tikhomirov IA, Rabasa A, Yang E, Gracia E, Iznaga N, et al. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol Ther. 2011;11(4):373\u201382.","journal-title":"Cancer Biol Ther"},{"issue":"8","key":"8995_CR18","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.7150\/thno.19710","volume":"7","author":"R You","year":"2017","unstructured":"You R, Hua YJ, Liu YP, Yang Q, Zhang YN, Li JB, et al. Concurrent Chemoradiotherapy with or without anti-EGFR-targeted treatment for stage II-IVb nasopharyngeal carcinoma: retrospective analysis with a large cohort and long follow-up. Theranostics. 2017;7(8):2314\u201324.","journal-title":"Theranostics"},{"key":"8995_CR19","first-page":"3383","volume":"8","author":"RP Zhai","year":"2015","unstructured":"Zhai RP, Ying HM, Kong FF, Du CR, Huang S, Zhou JJ, et al. Experience with combination of nimotuzumab and intensity-modulated radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. OncoTargets and therapy. 2015;8:3383\u201390.","journal-title":"OncoTargets and therapy"},{"issue":"2","key":"8995_CR20","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3727\/096504017X15079846743590","volume":"26","author":"W Fangzheng","year":"2018","unstructured":"Fangzheng W, Chuner J, Zhiming Y, Tongxin L, Fengqin Y, Lei W, et al. Long-term use of Nimotuzumab in combination with intensity-modulated radiotherapy and chemotherapy in the treatment of Locoregionally advanced nasopharyngeal carcinoma: experience of a single institution. Oncol Res. 2018;26(2):277\u201387.","journal-title":"Oncol Res"},{"issue":"3","key":"8995_CR21","doi-asserted-by":"publisher","first-page":"594","DOI":"10.7150\/jca.20461","volume":"9","author":"F Wang","year":"2018","unstructured":"Wang F, Sun Q, Jiang C, Liu T, Rihito A, Masoto S, et al. Additional induction chemotherapy to concurrent chemotherapy and intensity-modulated radiotherapy with or without nimotuzumab in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: a propensity score matched analysis. J Cancer. 2018;9(3):594\u2013603.","journal-title":"J Cancer"},{"key":"8995_CR22","doi-asserted-by":"crossref","unstructured":"Zhao C, Miao J, Shen G, Li J, Shi M, Zhang N, Hu G, Chen X, Hu X, Wu S, et al. Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial. Ann Oncol. 2019;30:637\u201343.","DOI":"10.1093\/annonc\/mdz020"},{"key":"8995_CR23","doi-asserted-by":"crossref","unstructured":"Svajdova M, Sicak M, Dubinsky P, Slavik M, Slampa P, Kazda T: Recurrent Nasopharyngeal Cancer: Critical Review of Local Treatment Options Including Recommendations during the COVID-19 Pandemic. Cancers (Basel) 2020, 12(12).","DOI":"10.3390\/cancers12123510"},{"key":"8995_CR24","doi-asserted-by":"crossref","unstructured":"Yu Y-H, Xia W-X, Shi J-L, Ma W-J, Li Y, Ye Y-F, Liang H, Ke L-R, Lv X, Yang J et al: A model to predict the risk of lethal nasopharyngeal necrosis after re-irradiation with intensity-modulated radiotherapy in nasopharyngeal carcinoma patients. Chinese Journal of Cancer 2016, 35(1).","DOI":"10.1186\/s40880-016-0124-0"},{"issue":"3","key":"8995_CR25","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.radonc.2012.06.012","volume":"104","author":"S-F Su","year":"2012","unstructured":"Su S-F, Huang Y. Xiao W-w, Huang S-M, Han F, Xie C-m, Lu T-X: clinical and dosimetric characteristics of temporal lobe injury following intensity modulated radiotherapy of nasopharyngeal carcinoma. Radiother Oncol. 2012;104(3):312\u20136.","journal-title":"Radiother Oncol"},{"key":"8995_CR26","doi-asserted-by":"crossref","unstructured":"YQ L, YM T, SH T, MZ L, G K, EHW O, C Z, TWK T, KW F, K S et al: Prognostic Model for Stratification of Radioresistant Nasopharynx Carcinoma to Curative Salvage Radiotherapy 2018, 36(9):891\u2013899.","DOI":"10.1200\/JCO.2017.75.5165"},{"issue":"3","key":"8995_CR27","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ijrobp.2021.01.041","volume":"110","author":"WT Ng","year":"2021","unstructured":"Ng WT, Soong YL, Ahn YC, AlHussain H, Choi HCW, Corry J, et al. International recommendations on Reirradiation by intensity modulated radiation therapy for locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2021;110(3):682\u201395.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08995-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08995-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08995-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T13:35:25Z","timestamp":1638279325000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08995-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,25]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8995"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08995-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-734636\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,25]]},"assertion":[{"value":"20 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present retrospective study was approved by the Ethics Committee of Fujian Cancer Hospital and all patients signed written informed consent prior to treatment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1274"}}